Bristol Myers Squibb and the associated logos are trademarks of Bristol Myers Squibb.
Bristol Myers Squibb is a global biopharmaceutical company advancing innovative therapies that address the complexities of liver disease, with a particular focus on unmet needs in conditions such as hepatocellular carcinoma (HCC) and liver fibrosis. Leveraging a legacy of scientific excellence and a pipeline rooted in immunology and oncology, Bristol Myers Squibb is developing novel mechanisms of action to transform the treatment landscape for patients with chronic and progressive liver disorders.
The company’s current liver-focused efforts are exemplified by Opdivo® (nivolumab), a first-in-class PD-1 immune checkpoint inhibitor approved for advanced hepatocellular carcinoma, either as monotherapy or in combination with other agents such as Yervoy® (ipilimumab). These immuno-oncology approaches are designed to enhance the body’s natural ability to fight cancer and have demonstrated durable responses in difficult-to-treat liver tumors.
Bristol Myers Squibb is also pursuing early- and mid-stage research programs aimed at intercepting liver fibrosis and modulating immune activity in liver-related autoimmune and metabolic diseases. The company’s strategic collaborations and investments in hepatology are driven by a commitment to uncovering the biological pathways underlying liver damage, regeneration, and immune response.
Recognizing the systemic nature of liver disease and its strong association with cardiovascular and metabolic comorbidities, Bristol Myers Squibb is uniquely positioned to deliver holistic care by drawing on its expertise across therapeutic areas. With a robust clinical trial network and a focus on inclusive access, the company is working to ensure its liver care innovations reach the diverse populations most affected by these high-burden diseases.
Through a combination of cutting-edge science, patient-centered research, and global partnerships, Bristol Myers Squibb aims to redefine the standard of care for liver disease and offer new hope to patients around the world.
